StockNews.AI
SEPN
StockNews.AI
178 days

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

1. Law firm investigates potential securities violations by Septerna. Claims may affect stockholder rights. 2. Company halted Phase 1 clinical trial of SEP-786. Decision followed unexpected severe safety signals. 3. Two severe cases of elevated unconjugated bilirubin reported without typical liver enzyme increases. 4. Shares dropped 46% after trial discontinuation announcement. This rapid decline worsens investor sentiment.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Clinical trial failure and potential securities litigation have triggered immediate, sharp sell-offs. Similar events in biotech past, like trial halts at other small-cap firms, led to drastic price declines.

How important is it?

The dual issues of clinical trial discontinuation and potential securities law violations are extremely significant for SEPN, impacting its near-term price and investor confidence.

Why Short Term?

The immediate 46% drop and active legal investigation indicate a near-term impact. Although legal proceedings could extend, the primary reaction is already evident.

Related Companies

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN) on behalf of Septerna stockholders. Our investigation concerns whether Septerna has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On February 18, 2025, Septerna announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786, an oral small molecule PTH1R agonist for treating hypoparathyroidism, in healthy volunteers. Septerna stated that this decision was based on the observation of two unexpected severe (Grade 3) cases of elevated unconjugated bilirubin in the MAD portion of the trial, both occurring without corresponding increases in ALT, AST, or GGT liver enzyme levels. On this news, the price of Septerna shares declined by $6.09 per share, or approximately 46%, from $12.96 per share on February 14, 2025, to close at $6.87 on February 18, 2025. If you purchased or otherwise acquired Septerna shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News